JAK3 and neoplasm: In multiple cancer models, azaspirans and their derivatives have been tested as inhibitors of some tyrosine kinase proteins related to tumor progression, such as atiprimod (JAK2/JAK3 inhibitor) and lestaurtinib (JAK2 inhibitor), which present different tumor inhibition mechanisms [11,12].